Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation

Figure 1

AS-IV treatment mitigates clinical symptoms and improves the kidney function in DN rats. Diabetic rats were randomized and treated with vehicle or AS-IV by gavage daily for 12 weeks and as the DN and AS-IV groups, respectively. One group of control (NC) received normal chow and vehicle treatment. (a) Their body weights and blood glucose levels were measured longitudinally. (b) Their water and food consumption and 24 h urine amounts were measured at the end of the experiment. (c) Their renal index, 24 h urine proteins, 24 h urine creatinine, blood urea nitrogen, serum creatinine levels, and creatinine clearance rate were measured. Data are expressed as the of each group () of rats from three separate experiments, except for water, food, and urine amounts as the median and range. versus the NC group. ^# versus the DN group.

(a)

(b)

(c)